Table 4.
Presumptive causative pathogens in the two treatment groups
| CTRX n = 124 |
ABPC/SBT n = 139 |
|
|---|---|---|
| Streptococcus pneumoniae | 35 (10) | 26 (1) |
| MSSA | 0 | 2 |
| Haemophilus influenzae | 3 (1) | 3 |
| Klebsiella pneumoniae | 0 | 3 |
| Enterobacter cloacae | 0 | 1 |
| Pseudomonas aeruginosa | 0 | 3 |
| Moraxella catarrhalis | 2 (1) | 1 |
| Mycoplasma pneumoniae | 38 (10) | 28 (1) |
| Chlamydophila pneumoniae | 0 | 4 |
| Virus* | 2 | 1 |
| Unknown | 55 | 69 |
CTRX Ceftriaxone, ABPC/SBT Ampicillin/sulbactam, MSSA Methicillin-sensitive Staphylococcus aureus. The number of cases with other pathogens detected is indicated in parentheses. Sputum examinations were not possible in 58 cases of the CTRX group and 69 cases of the ABPC/SBT group (p = 0.711). Missing data were in three patients of the CTRX group vs in seven of the ABPC/SBT group for blood culture examination (p = 0.343), one vs one for Mycoplasma pneumoniae and Chlamydophila pneumoniae antibody tests (p = 1.000), 22 vs 19 for urinary antigen tests of Streptococcus pneumoniae and Legionella pneumophilia serogroup 1 (p = 0.398). *Diagnosed by influenza virus antigen using throat or nasal swab specimens